文献速递血栓与止血

阿哌沙班与达肝素治疗活动性恶性肿瘤相关静脉血栓栓塞:ADAM VTE试验

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
PubMed 文献 · J Thromb Haemost · 2019-11-28

ADAM VTE试验将300例癌症相关静脉血栓栓塞患者随机分配至阿哌沙班组或达肝素组,主要终点为大出血。

要点

  • 阿哌沙班治疗癌症相关VTE的大出血发生率低(0% vs 1.4%)。
  • 阿哌沙班显著降低复发性VTE风险(0.7% vs 6.3%,HR 0.099)。
  • 两组大出血或临床相关非大出血复合终点均为6%。

核心结论

  • 口服阿哌沙班治疗癌症患者VTE与大出血和VTE复发率低相关。

研究设计与样本

  • 随机对照试验,300例癌症相关VTE患者随机分组,287例纳入主要分析。

主要发现

  • 两组大出血或临床相关非大出血复合终点发生率均为6%。

关键数值与推荐

  • 阿哌沙班用法:10 mg每日两次共7天,随后5 mg每日两次共6个月。
  • 达肝素用法:200 IU/kg共1个月,随后150 IU/kg每日一次。

临床怎么用

  • 对于活动性恶性肿瘤相关VTE患者,可考虑使用阿哌沙班作为低分子肝素外的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-molecular-weight heparin is the guideline-endorsed treatment for cancer-associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients. OBJECTIVES: The primary outcome was major bleeding. Secondary outcomes included VTE recurrence and a composite of major plus clinically relevant non-major bleeding (CRNMB). PATIENTS/METHODS: Patients with cancer-associated VTE were randomly assigned to receive either apixaban 10 mg twice daily for seven days followed by 5 mg twice daily for six months or subcutaneous dalteparin (200 IU/kg for one month followed by 150 IU/kg once daily). RESULTS: Of 300 patients randomized, 287 were included in the primary analysis. Metastatic disease was present in 66% of subjects; 74% were receiving concurrent chemotherapy. Major bleeding occurred in 0% of 145 patients receiving apixaban, compared with 1.4% of 142 patients receiving dalteparin [P = .138; hazard ratio (HR) not estimable because of 0 bleeding event in apixaban group]. Recurrent VTE occurred in 0.7% of apixaban, compared to 6.3% of dalteparin patients [HR 0.099, 95% confidence interval [CI], 0.013-0.780, P = .0281). Major bleeding or CRNMB rates were 6% for both groups. CONCLUSIONS: Oral apixaban was associated with low major bleeding and VTE recurrence rates for the treatment of VTE in cancer patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2019. PMID: 31630479. doi:10.1111/jth.14662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。